search
Back to results

Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy? (WEDGE-HCM)

Primary Purpose

Hypertrophic Cardiomyopathy

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Exercise training
Sponsored by
Bispebjerg Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hypertrophic Cardiomyopathy focused on measuring hypertrophic cardiomyopathy, exercise training, PCWP

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. ≥18 years at the time of screening
  2. Documented phenotypic HCM (maximal wall thickness ≥15mm, or ≥13mm in a first degree relative with a definite or likely disease causing genetic mutation (appendix 1)
  3. Not exercising regularly (dedicated moderate or high-intensity exercise >1 hour weekly)
  4. NYHA class I-IV.

Exclusion Criteria:

  1. Phenocopies (i.e. syndromes, metabolic disorders (appendix 2))
  2. A history of exercise induced syncope within the last year, severe angina (CCS III-IV), hemodynamically severe valvular disorders
  3. Scheduled septal reduction therapy, less than 3 months after septal reduction therapy or known LVOT gradient above 30 mmHg at rest
  4. Severe hypertension (Systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg).
  5. Inability to exercise due to orthopedic or other non-cardiovascular limitations.
  6. Pregnancy
  7. Changes in medication that may affect exercise capacity and/or hemodynamics (i.e. beta blockers and calcium channel blockers)
  8. Any condition (eg, psychiatric illness) or situation that, in the investigator's opinion, could put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.

Sites / Locations

  • Rigshospitalet

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Usual activity level

Exercise training

Arm Description

12 weeks of usual activity level

12 weeks of moderate intensity exercise training, 3 hours a week

Outcomes

Primary Outcome Measures

Change from baseline to follow-up in PCWP at 25 W
Pulmonary capillary wedge pressure (mmHg)

Secondary Outcome Measures

Pulmonary capillary wedge pressure
At rest, at 25% and 50% of the maximum workload and at maximum workload ( measured as mmHg)
Workload adjusted Pulmonary capillary wedge pressure
At rest, at 25% and 50% of the maximum workload and at maximum workload, measured as mmHg/kg/W
Systemic vascular resistance
Resting and exercise systemic vascular resistance at rest, 25 W, 25% and 50% of the maximum workload and at maximum workload ( measured as mmHg)
Exercise capacity
Measured as watt at maximum workload
Heart rate
At rest, during exercise and at maximum exercise capacity (beats/min)
Blood pressure
At rest, at maximum workload, 6 minutes after cease of workload (mmHg)
Cardiac index
At rest, 25W and at maximum workload (L/min/m2):
Arterio-venous difference
At rest, 25W and at maximum workload (ml O2/L)and workload corrected (mlO2/L/W)
VO2 max
Measered as ml O2/min/kg
Quality of life questionnaire
Measured by Kansas City Cardiomyopathy score
NT-Pro-BNP
(pmol/L)
Troponin-T
(mmol/L)
Echocardiographic parameters
At rest: E/e'-ratio, E/A-ratio, deceleration time, LVOT gradient (mmHg). During exercise from 25W to maximum workload: E/e'-ratio, E/A-ratio, deceleration time, LVOT gradient(mmHg).

Full Information

First Posted
May 9, 2018
Last Updated
April 27, 2023
Sponsor
Bispebjerg Hospital
Collaborators
Rigshospitalet, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT03537183
Brief Title
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
Acronym
WEDGE-HCM
Official Title
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy? - A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
September 1, 2018 (Actual)
Primary Completion Date
April 1, 2023 (Actual)
Study Completion Date
April 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bispebjerg Hospital
Collaborators
Rigshospitalet, Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Aims and objectives: The primary objective of this study is to assess whether a structured exercise program improves cardiac relaxing properties in patients with hypertrophic cardiomyopathy (HCM). Background: HCM is a hereditary disease in which the myocardium becomes thickened without an identifiable cause (other than genetic). It is the most common genetic cardiovascular disease with an estimated prevalence of 1/500 (i.e. 10.000 affected individuals in Denmark). The majority of patients with HCM suffers from shortness of breath and reduced exercise capacity due to increased left ventricular (LV) stiffness. Exercise training has been shown to improve exercise capacity and symptoms in patients with HCM, but the mechanisms responsible for this improvement are not known. Methods and materials: The study is a randomized, single blinded, prospective, controlled clinical trial. Eighty patients are recruited from outpatient clinics in the Capital Region of Denmark. Patients are randomized in a 1:1 ratio to 12 week of moderate-intensity exercise training or usual activity level. Assessments will include right heart catheterization, echocardiography, cardiopulmonary exercise testing, blood-samples, quality of life, and, in a subgroup of patients, cardiac magnetic resonance imaging. The primary end-point is change in LV filling pressure assessed as pulmonary capillary wedge pressure at 25 W workload. Expected outcome and perspectives: The investigators hypothesize that an exercise training program will reduce cardiac stiffness and improve symptoms in patients with HCM. Training of HCM patients has long been debated and the topic is poorly researched. The effects of exercise on hemodynamics in HCM patients are unknown and a better understanding of these mechanisms is pivotal for improving treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertrophic Cardiomyopathy
Keywords
hypertrophic cardiomyopathy, exercise training, PCWP

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual activity level
Arm Type
No Intervention
Arm Description
12 weeks of usual activity level
Arm Title
Exercise training
Arm Type
Active Comparator
Arm Description
12 weeks of moderate intensity exercise training, 3 hours a week
Intervention Type
Other
Intervention Name(s)
Exercise training
Intervention Description
12 weeks, 3 hours a week, moderate intensity exercise training
Primary Outcome Measure Information:
Title
Change from baseline to follow-up in PCWP at 25 W
Description
Pulmonary capillary wedge pressure (mmHg)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Pulmonary capillary wedge pressure
Description
At rest, at 25% and 50% of the maximum workload and at maximum workload ( measured as mmHg)
Time Frame
12 weeks
Title
Workload adjusted Pulmonary capillary wedge pressure
Description
At rest, at 25% and 50% of the maximum workload and at maximum workload, measured as mmHg/kg/W
Time Frame
12 weeks
Title
Systemic vascular resistance
Description
Resting and exercise systemic vascular resistance at rest, 25 W, 25% and 50% of the maximum workload and at maximum workload ( measured as mmHg)
Time Frame
12 weeks
Title
Exercise capacity
Description
Measured as watt at maximum workload
Time Frame
12 weeks
Title
Heart rate
Description
At rest, during exercise and at maximum exercise capacity (beats/min)
Time Frame
12 weeks
Title
Blood pressure
Description
At rest, at maximum workload, 6 minutes after cease of workload (mmHg)
Time Frame
12 weeks
Title
Cardiac index
Description
At rest, 25W and at maximum workload (L/min/m2):
Time Frame
12 weeks
Title
Arterio-venous difference
Description
At rest, 25W and at maximum workload (ml O2/L)and workload corrected (mlO2/L/W)
Time Frame
12 weeks
Title
VO2 max
Description
Measered as ml O2/min/kg
Time Frame
12 weeks
Title
Quality of life questionnaire
Description
Measured by Kansas City Cardiomyopathy score
Time Frame
12 weeks
Title
NT-Pro-BNP
Description
(pmol/L)
Time Frame
12 weeks
Title
Troponin-T
Description
(mmol/L)
Time Frame
12 weeks
Title
Echocardiographic parameters
Description
At rest: E/e'-ratio, E/A-ratio, deceleration time, LVOT gradient (mmHg). During exercise from 25W to maximum workload: E/e'-ratio, E/A-ratio, deceleration time, LVOT gradient(mmHg).
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Left ventricular fibrosis
Description
(assessed as late gadolinum enhancement) and extracellular volume (assessed using T1-mapping) will be assessed in the subgroup of patients without contraindications to CMR and will be correlated to LV filling pressures.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥18 years at the time of screening Documented phenotypic HCM (maximal wall thickness ≥15mm, or ≥13mm in a first degree relative with a definite or likely disease causing genetic mutation (appendix 1) Not exercising regularly (dedicated moderate or high-intensity exercise >1 hour weekly) NYHA class I-IV. Exclusion Criteria: Phenocopies (i.e. syndromes, metabolic disorders (appendix 2)) A history of exercise induced syncope within the last year, severe angina (CCS III-IV), hemodynamically severe valvular disorders Scheduled septal reduction therapy, less than 3 months after septal reduction therapy or known LVOT gradient above 30 mmHg at rest Severe hypertension (Systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg). Inability to exercise due to orthopedic or other non-cardiovascular limitations. Pregnancy Changes in medication that may affect exercise capacity and/or hemodynamics (i.e. beta blockers and calcium channel blockers) Any condition (eg, psychiatric illness) or situation that, in the investigator's opinion, could put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
Facility Information:
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?

We'll reach out to this number within 24 hrs